Drug News 15 to 21 April 2024
European Medicine Agency (EMA) The EMA’s Committee for Medicinal Products for Human Use (CHMP) is scheduled to hold its monthly meeting from April 22 to 25. US Food and Drug Administration (FDA) The FDA made the following decisions: New data from clinical trials (Phase 2, Phase 3) Here are the recent updates on Phase 2 […]
Zombie VCs in Lifescience?
Do you also see increasing VCs having issues with raising funds? Do you agree with this article in the life science funding sphere? Use the following to share your opinion https://survey.zohopublic.eu/zs/coDHby CNBC article: Rise of ‘zombie’ VCs haunts tech investors as plunging valuations hammer the industry
Life-Sciences Investment series, October 2022
Health Economia Life-Sciences Investment Series October 2022
Successfully investing in early life science assets, such as medical device projects, diagnostics, digital therapeutics or drug therapies, requires conducting thorough scientific due diligence, monitoring the development plan execution, and implementing a development risk assessment & mitigation plan.
Besides the challenging environment, we observed that this era is appropriate to successfully invest in Life Science assets. After interacting with several Biotech founders, we consistently observed that they need the investors’ advice and network, as much as the funds.